High Quality Cas 183552-38-7 - Telipressin acetate for injection – JYMed
High Quality Cas 183552-38-7 - Telipressin acetate for injection – JYMed Detail:
Terlipressin Acetate for injection
1mg/vial Strength
Indication: For the treatment of esophageal variceal bleeding.
Clinical application: intravenous injection.
Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection contains the active ingredient terlipress in, which is a synthetic pituitary hormone (this hormone is usually produced by the pituitary gland found in the brain).
It will be given to you by injection into a vein.
Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection is used for the treatment of:
• bleeding from dilated (widening) veins in the food pipe leading to your stomach (called bleeding oesophageal varices).
• emergency treatment of type 1 hepatorenal syndrome (rapidly progressive renal failure) in patients with liver cirrhosis (scarring of the liver) and ascites (abdominal dropsy).
This medicine will always be given to you by a doctor into your vein. The doctor will decide the most appropriate dose for you and your heart and blood circulation will be continuously monitored during the injection. Please ask your doctor for further information regarding its use.
Use in adults
1. Short term management of bleeding oesophageal varices
Initially 1-2 mg terlipress in acetate (5-10 ml of Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection) is given by injection into your vein. Your dose will depend on your body weight.
After the initial injection, your dose may be reduced to 1 mg terlipress in acetate (5 ml) every 4 to 6 hours.
2. Type 1 hepatorenal syndrome
The usual dose is 1 mg terlipress in acetate every 6 hours for at least 3 days. If the reduction of serum creatinine is less than 30 % after 3 days of treatment your doctor should consider doubling the dose to 2 mg every 6 hours.
If there is no response to Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection or in patients with complete response, treatment with Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection should be interrupted.
When a reduction in serum creatinine is seen, treatment with Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection should be maintained to a maximum of 14 days.
Use in the elderly
If you are over 70 years of age speak with your doctor before you receive Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection.
Use in patients with kidney problems
Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection should be used with caution in patients with long standing kidney failure.
Use in patients with liver problems
No dose adjustment is required in patients with liver failure.
Use in children and adolescents
Terlipress in acetate EVER Pharma 0.2 mg/ml solution for injection is not recommended for use in children and adolescents due to insufficient experience.
Duration of treatment
The use of this medicine is limited to 2 – 3 days for short term management of bleeding oesophageal varices and to a maximum of 14 days for treatment of type 1 hepatorenal syndrome, depending on the course of your condition.
Product detail pictures:
Related Product Guide:
Pretreatment with β-Boswellic Acid Improves Blood Stasis Induced Endothelial Dysfunction: Role of eNOS Activation | Trelstar(Triptorelin Pamoate)
TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease | Trelstar(Triptorelin Pamoate)
We attempt for excellence, support the customers", hopes to become the top cooperation team and dominator enterprise for staff, suppliers and shoppers, realizes worth share and continual marketing for High Quality Cas 183552-38-7 - Telipressin acetate for injection – JYMed , The product will supply to all over the world, such as: Pakistan, Japan, Peru, We have our own registered brand and our company is developing rapidly owing to high quality products, competitive price and excellent service. We sincerely hope to establish business relations with more friends from home and abroad in the near future. We look forward to your correspondence.
By Barbara from Hamburg - 2015.06.12 16:22
We feel easy to cooperate with this company, the supplier is very responsible, thanks.There will be more in-depth cooperation.
By Miguel from Toronto - 2015.02.12 14:52
